Syncom Formulations (India) Ltd. — Interim / Quarterly Report 2023

Aug 14, 2023

Syncom Formulations (India) Limited ____________A WHO-GMP & ISO 9001-2015 Certified Company

SYNCOM/SE/2023-24

CIN No. : L24239MH1988PLC047759

14August, ²⁰²³

Online filing at: www.Iisting.bseindia.com and https://neaps.nseindia.com/NELISTI_CORP/login.isn

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30"" June, 2023.

Dear Sir/Ma'am,

This is in continuation of our letter no. SYNCOM/SE/2023-24 dated 3" August 2023 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30" June, 2023.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30"June, 2023, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 14"August, 2023.

The Board Meeting commenced at ¹¹ :00 A.M. and concluded at..2:.1.S:. P.M.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website ofthe company.

You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record.

Thanking You Yours Faithfully For, SYNCOM FORMULATIONS (INDIA) LIMITED

. (fr....^{~ o} CS VAISHALI AGRAWAL f( [5' COMPANY SECRETARY & . COMPLIANCE OFFICER VAISHALI AGRAWAL Digitally signed by VAISHALI AGRAWAL Date: 2023.08.14 14:29:19 +05'30'

Encl: Unaudited Standalone and isokidled ancial Results and Limited Review Report.

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), MUMBAI-400 093, INDIA. Tel. : +91-22-30887744-54 Fax : +91-022-30887755 Email : sfil87@hotmail.com Corp. Off. : 207, Saket Nagar, INDORE - 452 018, M.P., INDIA. Tel. : +91-731-2560458/2700458 E-mail : info@sfil.in Works : 256-257, Sector-1, PITHAMPUR Dist-Dhar, M.P. - ⁴⁵⁴ 775, INDIA. Tel. :+ 91-7292-403122/407039 Email : info@sfil.in Website : http://www.sfil.in

SANJAY MEHTA & ASSOCIATES

Chartered Accountants

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Third Month ended 30" June, 2023 pursuant to Regulation ³³ of the SEBI (LODR) Regulations, 2015

To, The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company"), for the period ended June, 30, ²⁰²³ (the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue ^a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation ³³ of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates Chartered Accou ants FRN: 011524C CA Manish Mittal (Partner) M. No. 079452 UDIN: 23079452BGQYAM8550

Place: Indore Date: 14 August, ²⁰²³

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off • 7.Niraj Industrial Estate.Off Mahakali Caves RoadAndhen (E.) Mumbai-400093

Works. 256-257. Sector.1 Pithampur Dist Dhar.454775

^E Mail.- finance@sfilin, Website.- www.sfl.in, CIN-L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

s.	Particulars	Quarter Ended			Year Ended
No.		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		Unaudited	Audited*	Unaudited	Audited
1	Revenue from Operations	5936.43	6136.92	5140 04	22464 39
2	Other Income	187.74	677.94	297 97	1460.95
3	Total Income ( 1 + 2 )	6124.17	6814.86	5438.01	23925.34
4	EXPENSES		2554.84	2303.28	9946 06
	( a ) Cost of materials consumed ( b ) Purchases of Stock-in-Trade	2265.31 914.08	1321.16	867 06	4261 14
	( c ) Changes in inventories of finished goods, Stock-in- Trade and work-in			152 08	5.03
	progress (d)Employee	390.53	(96.49) 719.77	497 86	2586.56
	benefits expense	762.81 11217	129 19	50 37	313 02
	( e ) Finance costs	110.00	116.78	99.50	453 93
	( f ) Depreciation and amortization expense	987.93	1043. 86	971 10	3704.28
	( g ) Other expenses Total expenses (4 )	5542.83	5789.11	4941.25	21270.02
	ProfiU(loss) before exceptional iteins and tax (3- 4)	581.34	1025.75	496.76	2655.32
5	Exceptional Items	0.00	133	0.00	1.33
6	before tax(5 Profit/(loss) -6)	581.34	1027.08	496.76	2656.65
7 8	Tax expense				664 84
	( 1 i Current tax	160.30 (3.81)	258 84 (78.41)	103 00 7 00	(15.26)
	(2) Deferred tax from continuing operations Profit (Loss) for the period (7-8)
9		424.85	846.65	386.76	2007.07 0 00
10	Profit/(loss) from discontinued operations	0 00 000	0.00 0.00	0 00 0 00	0 00
11	Tax expense of discontinued operations ProfiU(loss) from Discontinued operations (after tax) (10-11)
12		0.00	0.00	0 00 386.76	0 00 2007.07
13	ProfiU(loss) for the period ( 9 + 12)	424.85	846.65
14	Other Comprehensive Income A(i)ltems that will not be reclassified to profit or loss	0 00	0.00	0.00	0 JO
	(ii) Income tax relating to items that will not be reclassified to profit or loss				0
		0 00	0 00	O00	196. 36
	B (i) Items that will be reclassified to profit or loss	206.77	48.85	(85.36)
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0 00	C, 00
15	(XIII+XIV) (Comprising Total Comprehensive Income for the period
	Profit (Loss) and Other Comprehensive Income for the period)	631.62	895.50	301.40	2203.43
		9400.00	9400.00	940C.00	9400.00
16 17	Paid up Share Capital of the Company (Face Value 1/-) Reserves excluding revaluation reserves				16201.47
18	Earnings per equity share (for continuing operation):
	(1) Basic	0.07	0 10	0.03 0.03	024 0.24
	(2) Diluted	0.07	0 10
19	Earnings per equity share (for discontinued operation)	0 00	0.00	0.00	0 00
	(1) Basic (2) Diluted	0 00	0 00	0 00	0 00
20	Earnings per equity share (for discontinued & continuing operations)
		0.07	O10	0.03	0.24
	(1) Basic l2) Diluted	0.07	O10	0.03	0 24
				7	2
Place: Indore				55
Date:	14/08/2023		g%
				i ~ -4 •.~~	-
			l F .c	'l 1773}	dar'mal Shankarlal Bankda
			Z- Q	Chairman	& wnoletime Director

Q; Chairman & wnoletime Director 4s4d? DIN: ^00023050

.-.

Regd Off .- 7 Niraj Industrial EstateOit Mahakali Caves RoadAndheri (E) Mumbai-400093

Works.- 256-257. Sector1 Pithamput. Dist Dhar-454775

• ^E Mail.- finance@sfit.in, Website www.sfil.in, CIN L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY UNAUDITED RESULTS

					Rs. In Lacs
			Quarter Ended
S. No.	Particulars	30-06-2023	31-03-2023	30-06-2022	31-03-2023
		Unaudited	Audited*	Unaudited	Audited
1	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	5559 41	5932.04	4845 80	21037.66
	b) Trading of Commodities	456.98	803.01	510.41	255240 335 28
	c) Renting of Property	107.78	79 81	81.80	23925.34
	Total Segment Revenue	6124.17	6814.86	5438.01
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Revenue from Operations	6124.17	6814.86	5438.01	23925.34
2	Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	595.98	1081 39	447 63	2620 14
	b) Trading of Commodities	-5.70	1325	17 70	32 43
	c) Renting of Property	103.23	61.63	81.80	317 10
	Total Profit before tax	693.51	1156.27	547.13	2969.67
	L.ess i) Interest	11217	129 19	50 37	313 02
	ii) Other Un-allocable Expenditure	0 00	0.00	0 00	0.00
	Profit before tax	581.34	1027.08	496.76	2656.65
3	(Segment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	3203886	32002 05	3130892	32002 05
	b) Trading of Commodities	980.14	958.89	472 73	958 89
	c) Renting of Property	473345	0.00	4749.89	473345
	Total Segment Asset	37752.45	32960.94	36531.53	37694.39
	Un-allocable Assets	0.00		0.00
	Net Segment Asset	37752.45	32960.94	36531.53	37694.39
	Segment Liabilities
	a) Pharmaceuticals Drugs & Formulations	11095 28	11749 56	12168 52	11749.56
		260.49	179 91	221 75	179.91
	b) Trading of Commodities c) Renting of Property	163 56	163.44	158 81	133 44
	Total Segment Liabilities	11519.33	12092.91	12549.08	12092.91
	Un-allocable Liabilities	0.00	0 00	000	0 C
	Net Segment Liabilities	11519.33	12092.91	12549.08	12092.91

Notes:-

¹ The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/08/2023

² These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

³ The company is operating in ³ segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

⁴ As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2023. The report does not have any impact on the above results and notes which needs explanation.

⁵ Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification

⁶ The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15.93,47.820 warrants to 15,93,47.820 equity shares of Rs. 1/- each issued at ^a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3446.33 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 585.17 Lakhs will be used in the subsequent period. Trial Production has been started from 30th June ²³ and Commerical Production will be Started by end of Aug ²³ . There is no deviation in the project till 30th June, 2023 and necessary report towards as required under regulation ³² being filed to the BSE Ltd. Separately Place: Indore ,t'[«^~if»

⁷ The Company has incorporated ³ (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. on 21st July, 2022 and Vinci! Biotech International Pvt. Ltd. on 25th July, 2022 The Subsidiary Companies have obtained Drug Licenses and other approvals from the Competent Authorities. , during the Quarter under review, these Subsidiary Companies have started Business Activities di =

Date: 14/08/2023

<f o\~ulations (India) Limited

\ lj

^Og g2-,

~

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Three Months ended 30" June, 2023 pursuant to Regulation ³³ ofthe SEBI (LODR) Regulations, 2015

To, The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

• I. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results ofSYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended June 30, 2023 (""the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations. 2015, as amended including relevant circular issued by the SEBI from time to time.
• 1. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015. as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410."Review of Interim Financial Information performed by the Independent Auditor ofthe Entity". issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

S. No.	ofthe Name Company	with the an
1.	Biotech Pvt. Ltd. Santa	Wholly Subsidiary Owned
2.	Pvt. Ltd. Pharma nmex S	Subsidiar Wholl Owned
3.	Vincit Biotech International Pvt. Ltd.	Subsidiary Wholly Owned

1. The Statement includes the results of the following entity:

1. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations. 2015.including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates Chartered Accountants FRN: 0l 1524C

INDORE .....,

@ 4

5}

°

CA Manish Mittal (Partner) M. No. 079452 UDIN: 23079452BGQYAN3397

Place: Indore Date: 14" August 2023

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

^E Mail.- finance@sfl.in, Website - wwwsfil.in, CIN.- L24239MH1988PLC047759

	CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023			(Rs.In Lakhs)	( Except EPS)
S. No.	Particulars		Quarter Ended
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	5983 58	6097.95	5140.04	22425 42
2	Other Income	187.47	676.98	297 97	1459.99
3	Total Income ( 1 + 2 )	6171.05	6774.93	5438.01	23885.41
4	EXPENSES
	( a ) Cost of materials consumed	2265 31	2554.84	2303.28	9946 06
	( b) Purchases of Stock-in-Trade ( c ) Changes in inventories of finished goods, Stock-in- Trade and	92142	1321 16	867 06	4261. 14
	work-in-progress	368 22	(139. 13)	152 08	(37 61)
	( d ) Employee benefits expense	762.81	719.77	497.86	2586.56
	( e ) Finance costs	11217	129. 27	50.37	313 10
	( f) Depreciation and amortization expense	110.00	11678	99 50	453 93
	( g ) Other expenses	1019.85	1045 17	971 10	3706 30
	Total expenses ( 4)	5559.78	5747.86	4941.25	21229.48
5	ProfiU(loss) before exceptional items and tax (3- 4)	611.27	1027.07	496.76	2655.93
6	Exceptional Items	0 00	1.33	0.00	1.33
7	Profit/(loss) before tax(5-6)	611.27	1028.40	496.76	2657.26
8	Tax expense:
	(1) Current tax	175.45	259.45	103 00	66545 (15.26)
	(2) Deferred tax	(3.81)	(78 41)	7.00
9	Profit (Loss) for the period from continuing operations (7-8)	439.63	847.36	386.76	2007.07
10	ProfiU(loss) from discontinued operations	0 00	0 00	0.00	0 00
11	Tax expense of discontinued operations	0 00	0 00	0 00	0 00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0 00	0.00	0.00	0.00
13	ProfiU(loss) for the period ( 9 + 12 )	439.63	847.36	386.76	2007.07
	Other Comprehensive Income
	A(i)ltems that will not be reclassified to profit or loss	0 00	0 00	0 00	0 00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0 00	0 00	0 00	0 00
	B (1) Items that will be reclassified to profit or loss	206 77	48 85	(85 36)	196 36
	(ii) Income tax relating to items that will be reclassified to profit or
	loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income the period (Xlll+XIV) for (Comprising Profit (Loss) and Other Comprehensive Income for
	the period)	646.40	896.21	301.40	2203.43
16	Paid up Share Capital of the Company (Face Value 1/-)	9400. 00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves				16201 47
18	Earnings per equity share (for continuing operation)
	(1) Basic	0.07	O10	0 03	O24
	(2) Diluted	0.07	0.10	0.03	0.24
19	Earnings per equity share (for discontinued operation):
	(1) Basic	000	000	000 0.00	0.00 0 00
	(2) Diluted Earnings per equity share (for discontinued & continuing operations)	000	0.00
20
	(1) Basic	0.07	0 10	0.03	0.24
	(2) Diluted	0.07	O10	0 03	024

Place: Indore Date: 14/08/2023 For, Sync ·cmulations (India) Limited

EE SYNCOM FORMULATIONS (INDIA) LIMITED

Rega.Of .- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

^E Mail:- finance@sfil in. Website- www.sfil.in, CIN .- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RES ULTS ALONG WITH QUARTERLY UNAUDITED RESULTS

Year Ended S. No. Particulars 31-03-2023 31-03-2023 30-06-2023 30-06-2022 Unaudited Audited Unaudited Audited* Segment Revenue 1 5606 59 5892 11 a) Pharmaceuticals Drugs & Formulations 4845.80 255240 b) Trading of Commodities 456.98 803.01 510.41 107 48 c) Renting of Property 79.81 81.80 335 28 Total Segment Revenue 23885.41 6171.05 6774.93 5438.01 Less: Inter Segment Revenue 0.00 0.00 0.00 Revenue from Operations 6171.05 6774.93 5438.01 23885.41 Segment Results Profit(+)/Loss(-) before tax 2 and interest from each segment a) Pharmaceuticals Drugs & Formulations 1082.79 447.63 626.21 b) Trading of Commodities -5.70 13.25 17.70 6163 8180 10293 c) Renting of Property Total Profit before tax 1157.67 547.13 723.44 11217 129 27 Less: i) Interest 50.37 ii) Other Un-allocable Expenditure 0.00 0.00 0.00 Profit before tax 611.27 1028.40 496.76 (Segment Asset-Segment Liabilities) 3 Segment Asset a) Pharmaceuticals Drugs & Formulations 3130892 32085.85 32090.72 b) Trading of Commodities 958.89 472 73 980.14 473345 c) Renting of Property 0 00 4749 89 36531.53 Total Segment Asset 33049.61 37799.44 Un-allocable Assets 0.00 0.00 Net Segment Asset 37799.44 36531.53 37783.06 33049.61 Segment Liabilities 12168 52 11838.21 a) Pharmaceuticals Drugs & Formulations 11127.46 11838.21 b) Trading of Commodities 221.75 179.91 260.49 163 56 16344 158.81 c) Renting of Property Total Segment Liabilities 12181.56 12549.08 11551.51 Un-allocable Liabilities 0.00 0 00 0.00 Net Segment Liabilities 11551.51 12181.56 12549.08 Notes:- 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/08/2023. 2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. e 3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property. particulars of segment wise results are given as required. 4 As required under Regulation 33 of SEBI (LODR) Regulations., 2015 the limited review by the Statutory Audtors have been completed for the quarter ended on 30th June, 2023. The report does not have any impact on the above results and notes which needs explanation. 5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 6 The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs 4031 50 Lakhs 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs Out of which the company has already utilized the amount of Rs. 3446.33 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 585.17 Lakhs will be used in the subsequent period. Trial Production has been started from30th June 23 and commercial Production will be started by end of Aug. 23 There is no deviation in the project till 30th June 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately 7 The Company has incorporated 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. on 21st July and Vincit Biotech International Pvt. Ltd. on 25th July, 2022 .The Subsidiary Companies have obtained Drug Licenses and other approvals from the a Competent Authorities. , during the Quarter under review, these Subsidiary Companies have started Business Activities 2 8 The Company is not having any Subsidianes as on 30th June, 2022 The Company has provided Statandalo9?"9!"" kns 2 z or 30th June. 2022 For / Comparing the same wth 3oh June, 2023 on Consolidated basis ir hu s a lauons l (India) Limited " Pace: Indor r, 2l , o Date: 14/08/2023 i Lu. ,6cj ' <ks4ar I sakda e snankarar i - n s wnote@mer a s .A m DIN: 00023050 --·-</ks4ar
				Quarter Ended
						2099773
						2620.83
						3243
						317 10
						2970.36
						313 10
						0.00
						2657.26
						32090.72
						958 89
						4733 45
						37783.06
						179.91
						16344
						12181.56
						12181.56
		2022
						ector

• ⁵ Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
• ⁶ The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs 1/- each issued at ^a premium of Rs. 1.53 per share aggregating Rs ⁴⁰³¹ 50 Lakhs Out of which the company has already utilized the amount of Rs. 3446.33 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 585.17 Lakhs will be used in the subsequent period. Trial Production has been started from30th June ²³ and commercial Production will be started by end of Aug. 23 There is no deviation in the project till 30th June 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately
• ⁷ The Company has incorporated ³ (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. on 21st July ²⁰²² and Vincit Biotech International Pvt. Ltd. on 25th July, 2022 .The Subsidiary Companies have obtained Drug Licenses and other approvals from the Competent Authorities. , during the Quarter under review, these Subsidiary Companies have started Business Activities